OBJECTIVE:

To determine the 5-year survival (global and disease-free) after the treatment of patients with breast cancer at the Instituto Jalisciense de Cancerología.

MATERIALS AND METHODS:

Observational, descriptive cross-sectional, retrospective study of patients diagnosed with breast cancer treated during 2013 in the breast clinic service of the Instituto Jalisciense de Cancerología, Guadalajara. The five-year global and disease-free survival was established from the time elapsed from the diagnosis until the occurrence of an event (recurrence, metastasis or death) or date of last contact, with a limit to December 2018.

RESULT:

311 files were reviewed, but only 172 were included for the analysis of overall survival and disease-free survival at five years. The average age at diagnosis was 51.4 years. The most repeated stage was IIIA, determined in 64 patients (37.4%), IIA in 38 patients (22.2%), IIB in 19 patients (11.1%), AI and IIIC each with 15 patients (8.8%). The probability of five-year global survival was 78.5%. 24.4% presented recurrence with an average survival of 46.8 months. Statistical significance was demonstrated between stage, histological grade, result of immunohistochemistry and lymph node invasion and survival.

CONCLUSIONS:

This research represents an effort to establish the five-year survival of our patients. In the population studied, survival had acceptable and comparable values with other national and international studies and reflects the good medical practice of our institution.